Proteome Sciences plc
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in pla… Read more
Proteome Sciences plc (PMSNF) - Net Assets
Latest net assets as of June 2025: $-8.58 Million USD
Based on the latest financial reports, Proteome Sciences plc (PMSNF) has net assets worth $-8.58 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.35 Million) and total liabilities ($16.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-8.58 Million |
| % of Total Assets | -102.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 658.97 |
Proteome Sciences plc - Net Assets Trend (1994–2024)
This chart illustrates how Proteome Sciences plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Proteome Sciences plc (1994–2024)
The table below shows the annual net assets of Proteome Sciences plc from 1994 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-6.52 Million | -112.52% |
| 2023-12-31 | $-3.07 Million | -263.70% |
| 2022-12-31 | $-843.00K | +69.62% |
| 2021-12-31 | $-2.77 Million | +17.36% |
| 2020-12-31 | $-3.36 Million | +8.05% |
| 2019-12-31 | $-3.65 Million | +4.35% |
| 2018-12-31 | $-3.82 Million | -49.26% |
| 2017-12-31 | $-2.56 Million | -1253.44% |
| 2016-12-31 | $-189.00K | +83.64% |
| 2015-12-31 | $-1.16 Million | -31.55% |
| 2014-12-31 | $-878.00K | +60.09% |
| 2013-12-31 | $-2.20 Million | -186.98% |
| 2012-12-31 | $-766.53K | -123.24% |
| 2011-12-31 | $3.30 Million | -54.30% |
| 2010-12-31 | $7.22 Million | +178.14% |
| 2009-12-31 | $-9.24 Million | -64.26% |
| 2008-12-31 | $-5.62 Million | -159.77% |
| 2007-12-31 | $-2.17 Million | -183.66% |
| 2006-12-31 | $2.59 Million | -67.04% |
| 2005-12-31 | $7.85 Million | -10.82% |
| 2004-12-31 | $8.80 Million | -25.67% |
| 2003-12-31 | $11.84 Million | +0.02% |
| 2002-12-31 | $11.84 Million | +371.94% |
| 2001-12-31 | $2.51 Million | -4.96% |
| 2000-12-31 | $2.64 Million | +2414.29% |
| 1999-12-31 | $105.00K | -89.82% |
| 1998-12-31 | $1.03 Million | -64.05% |
| 1997-12-31 | $2.87 Million | +793.46% |
| 1996-12-31 | $321.00K | -76.24% |
| 1995-12-31 | $1.35 Million | +600.37% |
| 1994-12-31 | $-270.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Proteome Sciences plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7632900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.95 Million | % |
| Other Comprehensive Income | $15.41 Million | % |
| Other Components | $51.47 Million | % |
| Total Equity | $-6.52 Million | 100.00% |
Proteome Sciences plc Competitors by Market Cap
The table below lists competitors of Proteome Sciences plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NAT ABSOLUTE TECHNOLOGIES PUBLIC COMPANY LIMITED
BK:NAT
|
$5.60 Million |
|
Lahav LR Real Estate Ltd
TA:LAHAV
|
$5.60 Million |
|
Trainers House Oyj
HE:TRH1V
|
$5.60 Million |
|
Raen S.A.
WAR:RAE
|
$5.60 Million |
|
Godolphin Resources Ltd
AU:GRL
|
$5.60 Million |
|
JAPAN LOGISTICS FUND INC.
F:8UT
|
$5.59 Million |
|
Fiberweb (India) Limited
NSE:FIBERWEB
|
$5.59 Million |
|
Alliance Developpement Capital SIIC SE
PA:ALDV
|
$5.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Proteome Sciences plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -3,066,000 to -6,516,000, a change of -3,450,000.
- Net loss of 3,406,000 reduced equity.
- Other comprehensive income decreased equity by 42,999.
- Other factors decreased equity by 1,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.41 Million | -52.27% |
| Other Comprehensive Income | $-43.00K | -0.66% |
| Other Changes | $-1.00K | -0.02% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Proteome Sciences plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | $0.00 | $0.03 | x |
| 1996-12-31 | $0.00 | $0.03 | x |
| 1997-12-31 | $0.04 | $0.03 | x |
| 1998-12-31 | $0.01 | $0.03 | x |
| 1999-12-31 | $0.00 | $0.03 | x |
| 2000-12-31 | $0.03 | $0.03 | x |
| 2001-12-31 | $0.03 | $0.03 | x |
| 2002-12-31 | $0.11 | $0.03 | x |
| 2003-12-31 | $0.10 | $0.03 | x |
| 2004-12-31 | $0.07 | $0.03 | x |
| 2005-12-31 | $0.06 | $0.03 | x |
| 2006-12-31 | $0.02 | $0.03 | x |
| 2007-12-31 | $-0.02 | $0.03 | x |
| 2008-12-31 | $-0.04 | $0.03 | x |
| 2009-12-31 | $-0.07 | $0.03 | x |
| 2010-12-31 | $0.04 | $0.03 | x |
| 2011-12-31 | $0.02 | $0.03 | x |
| 2012-12-31 | $0.00 | $0.03 | x |
| 2013-12-31 | $-0.01 | $0.03 | x |
| 2014-12-31 | $0.00 | $0.03 | x |
| 2015-12-31 | $-0.01 | $0.03 | x |
| 2016-12-31 | $0.00 | $0.03 | x |
| 2017-12-31 | $-0.01 | $0.03 | x |
| 2018-12-31 | $-0.01 | $0.03 | x |
| 2019-12-31 | $-0.01 | $0.03 | x |
| 2020-12-31 | $-0.01 | $0.03 | x |
| 2021-12-31 | $-0.01 | $0.03 | x |
| 2022-12-31 | $0.00 | $0.03 | x |
| 2023-12-31 | $-0.01 | $0.03 | x |
| 2024-12-31 | $-0.02 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Proteome Sciences plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -69.70%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-68.30%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | 0.00% | 0.00% | 0.00x | 0.00x | $7.00K |
| 1996 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.57 Million |
| 1997 | -52.20% | 0.00% | 0.00x | 1.19x | $-1.78 Million |
| 1998 | -179.53% | 0.00% | 0.00x | 1.84x | $-1.95 Million |
| 1999 | -1171.43% | 0.00% | 0.00x | 7.64x | $-1.24 Million |
| 2000 | -53.22% | 0.00% | 0.00x | 1.60x | $-1.67 Million |
| 2001 | -79.05% | 0.00% | 0.00x | 1.50x | $-2.23 Million |
| 2002 | -34.71% | -2397.66% | 0.01x | 1.17x | $-5.29 Million |
| 2003 | -57.25% | -3987.77% | 0.01x | 1.22x | $-7.97 Million |
| 2004 | -59.06% | -7125.20% | 0.01x | 1.17x | $-6.08 Million |
| 2005 | -87.85% | -43106.25% | 0.00x | 1.22x | $-7.68 Million |
| 2006 | -217.85% | -8291.18% | 0.01x | 2.47x | $-5.90 Million |
| 2007 | 0.00% | -1974.44% | 0.04x | 0.00x | $-5.04 Million |
| 2008 | 0.00% | -544.64% | 0.13x | 0.00x | $-4.06 Million |
| 2009 | 0.00% | -307.04% | 0.21x | 0.00x | $-3.09 Million |
| 2010 | 63.21% | 45.72% | 0.64x | 2.16x | $3.84 Million |
| 2011 | -119.95% | -387.56% | 0.09x | 3.31x | $-4.29 Million |
| 2012 | 0.00% | -368.93% | 0.17x | 0.00x | $-4.18 Million |
| 2013 | 0.00% | -0.01% | 3525.05x | 0.00x | $-2.93 Million |
| 2014 | 0.00% | -0.02% | 2292.33x | 0.00x | $-3.48 Million |
| 2015 | 0.00% | -0.01% | 2250.09x | 0.00x | $-2.60 Million |
| 2016 | 0.00% | -0.01% | 2043.09x | 0.00x | $-2.26 Million |
| 2017 | 0.00% | -0.01% | 2531.36x | 0.00x | $-2.24 Million |
| 2018 | 0.00% | -0.01% | 2798.92x | 0.00x | $-931.20K |
| 2019 | 0.00% | 0.00% | 2359.77x | 0.00x | $514.20K |
| 2020 | 0.00% | 0.00% | 1863.52x | 0.00x | $630.80K |
| 2021 | 0.00% | 0.00% | 2249.18x | 0.00x | $349.50K |
| 2022 | 0.00% | 0.01% | 1909.11x | 0.00x | $1.41 Million |
| 2023 | 0.00% | -48.59% | 0.44x | 0.00x | $-2.14 Million |
| 2024 | 0.00% | -69.70% | 0.53x | 0.00x | $-2.75 Million |
Industry Comparison
This section compares Proteome Sciences plc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Proteome Sciences plc (PMSNF) | $-8.58 Million | 0.00% | N/A | $5.60 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |